Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other ju ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2019 Results Earnings Conference Call March 3, 2020 8:00 AM ET Company Participants Jenna Bosco - VP, IR & Senior VP of Corporate Communications Sean Power - CFO, Corporate Secretary & Treasurer Michael Weiss - Executive Chairman, CEO & President Conference Call Participants Alethia Young - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Ed White - H.C. Wainwright & Company Chris Howerton - Jefferies Mayank Mamtani - B. Riley FBR Operator Greetings, and welcome to t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number 1-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (Stat ...

TG THERAPEUTICS INVESTOR & ANALYST FIRESIDE CHAT EVENT TG Therapeutics ASH 2019 Investor & Analyst Event | --- | --- | --- | |-------|---------------------------------------------------|-------| | | | | | | PARTICIPANTS | | | • | Paul Barr, MD, University of Rochester | | | • | Javier Pinilla, MD, Moffitt Cancer Center | | | • | Pier Luigi Zinzani, MD, University of Bologna | | | • | Brian Koffman, MD, CLL Society | | | | | | | | Moderators | | | • | Alethia Young – Cantor Biotech Analyst | | | • | Michael ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 ___________________________________________ TG THERAPEUTICS, INC. (Exact name of regist ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Jenna Bosco - VP, IR & SVP, Corporate Communications Sean Power - CFO, Corporate Secretary & Treasurer Michael Weiss - Executive Chairman, CEO & President Conference Call Participants Matthew Kaplan - Ladenburg Thalmann & Co. Edward White - H.C. Wainwright & Co. Christopher Howerton - Jefferies Operator Greetings. Welcome to TG Therapeutics' Third Quarter 2019 Financial Results and Business ...

October 2019 TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to differ materially from t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 ___________________ TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State o ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2019 Earnings Conference Call August 9, 2019 8:30 AM ET Company Participants Jenna Bosco - SVP of Corporate Communications Sean Power - CFO Michael Weiss - Chairman and CEO Conference Call Participants Alethia Young - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Ed White - H.C. Wainwright Peter Lawson - SunTrust Robinson Humphrey Chris Howerton - Jefferies Operator Greetings and welcome to the TG Therapeutics Q2 2019 Earnings Conference Call. At this time, all pa ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Sean Power - Chief Financial Officer Michael Weiss - Executive Chairman & Chief Executive Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Ren Benjamin - Raymond James Ed White - H.C. Wainwright Pete Lawson - SunTrust Robinson Humphrey Matt Kaplan - Ladenburg Thalmann Operator Greetings and welcome to the TG Th ...